April 24, 2017 / 5:44 AM / 3 months ago

BRIEF-UCB Q1 Cimzia sales up at 317 million euros

1 Min Read

April 24 (Reuters) - UCB SA:

* Q1 immunology/Cimzia sales 317 million euros ($344 million) versus 281 million euros year ago

* Q1 Vimpat sales 239 million euros versus 188 million euros year ago

* Q1 Neupro sales 73 million euros versus 71 million euros year ago

* Q1 Keppra sales 210 million euros versus 168 million euros year ago

* Q1 revenue 1.124 million euros versus 974 million euros year ago

* Expects 2017 revenue to reach 4.25 - 4.35 billion euros

* Expects 2017 recurring EBITDA increase to 1.15 - 1.20 billion euros

* Core earnings per share are expected in the range of 3.70 – 4.00 euros based on an expected average of 188 million shares outstanding Source text for Eikon: bit.ly/2pbCUL5 Further company coverage: ($1 = 0.9216 euros) (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below